Liquidia (NASDAQ:LQDA) Raised to Strong-Buy at Lifesci Capital

Liquidia (NASDAQ:LQDA) was upgraded by Lifesci Capital to a “strong-buy” rating in a research report issued to clients and investors on Thursday,Zacks.com reports.

A number of other research analysts have also commented on the stock. HC Wainwright lifted their price objective on shares of Liquidia from $50.00 to $55.00 and gave the company a “buy” rating in a research note on Friday. Zacks Research downgraded shares of Liquidia from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 27th. Raymond James Financial restated a “strong-buy” rating on shares of Liquidia in a research report on Thursday. Wells Fargo & Company increased their price objective on Liquidia from $31.00 to $44.00 and gave the stock an “overweight” rating in a research report on Friday. Finally, Wall Street Zen raised Liquidia from a “hold” rating to a “buy” rating in a report on Saturday. Two analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $42.00.

Liquidia Stock Performance

NASDAQ LQDA traded up $1.51 on Thursday, reaching $36.03. The stock had a trading volume of 2,306,542 shares, compared to its average volume of 1,900,515. The stock has a market cap of $3.13 billion, a P/E ratio of -43.41, a price-to-earnings-growth ratio of 0.60 and a beta of 0.52. Liquidia has a 12-month low of $11.26 and a 12-month high of $46.67. The business’s 50-day moving average price is $37.10 and its 200 day moving average price is $30.89. The company has a debt-to-equity ratio of 6.19, a quick ratio of 1.96 and a current ratio of 2.20.

Liquidia (NASDAQ:LQDA) last announced its earnings results on Thursday, March 5th. The company reported $0.15 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.18). Liquidia had a negative return on equity of 237.79% and a negative net margin of 43.53%.The business had revenue of $92.02 million for the quarter. The business’s revenue for the quarter was up 3072.4% compared to the same quarter last year. As a group, equities analysts expect that Liquidia will post -1.51 earnings per share for the current year.

Insider Transactions at Liquidia

In other news, CAO Dana Boyle sold 1,580 shares of the stock in a transaction that occurred on Monday, January 26th. The stock was sold at an average price of $41.65, for a total transaction of $65,807.00. Following the completion of the transaction, the chief accounting officer directly owned 178,848 shares of the company’s stock, valued at approximately $7,449,019.20. This represents a 0.88% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, General Counsel Russell Schundler sold 27,289 shares of Liquidia stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $37.43, for a total value of $1,021,427.27. Following the completion of the sale, the general counsel owned 579,394 shares in the company, valued at approximately $21,686,717.42. This trade represents a 4.50% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 212,534 shares of company stock valued at $7,964,719 over the last 90 days. Insiders own 26.50% of the company’s stock.

Institutional Investors Weigh In On Liquidia

Institutional investors have recently made changes to their positions in the stock. Farallon Capital Management LLC grew its stake in shares of Liquidia by 1.1% during the 4th quarter. Farallon Capital Management LLC now owns 8,656,038 shares of the company’s stock worth $298,547,000 after purchasing an additional 90,400 shares during the period. Vanguard Group Inc. boosted its holdings in Liquidia by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 4,013,888 shares of the company’s stock worth $138,439,000 after buying an additional 52,671 shares in the last quarter. Opaleye Management Inc. boosted its holdings in Liquidia by 9.5% during the second quarter. Opaleye Management Inc. now owns 2,475,000 shares of the company’s stock worth $30,838,000 after buying an additional 215,000 shares in the last quarter. Caprock Group LLC grew its position in Liquidia by 9.3% during the fourth quarter. Caprock Group LLC now owns 1,783,921 shares of the company’s stock worth $61,527,000 after buying an additional 151,832 shares during the period. Finally, TCG Crossover Management LLC purchased a new position in Liquidia in the third quarter valued at about $38,887,000. 64.54% of the stock is currently owned by hedge funds and other institutional investors.

Liquidia News Summary

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Commercial momentum and profitability — Liquidia reported YUTREPIA net product sales of $90.1M in Q4 and $148.3M for 2025, achieved a second consecutive profitable quarter (Q4 net income $14.6M) and positive adjusted EBITDA, signaling rapid launch adoption and improving unit economics. GlobeNewswire Release
• Positive Sentiment: Balance sheet strength — the company ended 2025 with ~$190.7M in cash, improving liquidity and backing management’s plan to fund commercial expansion and clinical programs from operations. Quiver Quant Summary
• Positive Sentiment: Analyst upgrades and higher price targets — several firms raised ratings/targets after the quarter (HC Wainwright to $55, Needham to $54, BTIG to $50, Wells Fargo to $44), which supports further upside and likely contributed to intraday buying. Benzinga Analyst Roundup
• Neutral Sentiment: Mixed EPS headlines — Liquidia reported GAAP EPS of $0.15 for Q4. That missed some sell‑side consensus figures (~$0.33) but beat other estimates (Zacks cited $0.08), creating mixed investor interpretation of the results. Zacks Coverage
• Neutral Sentiment: Earnings materials and management commentary available — the slide deck and transcript provide color on commercial adoption, prescriber metrics and plans to fund L606 and other programs; useful for assessing sustainability of the launch. Earnings Presentation (Seeking Alpha)
• Negative Sentiment: Initial market reaction to the EPS headline — shares gapped down on the earnings headline before rebounding, showing sensitivity to EPS versus revenue/profitability nuance. That initial gap indicates headline risk if future quarters miss expectations. DefenseWorld: Gap Down
• Negative Sentiment: Insider and institutional sales — recent filings and summaries show notable insider sell activity and some large institutional reductions, which can weigh on sentiment if sustained. Fool: SEC Filing

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).